In re: Galectin Therapeutics, Inc. Securities Litigation, No. 16-10324, 2016 WL 7240146, ____ , F2d ___ (11th Cir. Dec. 15, 2016).
The Eleventh Circuit recently addressed the circumstances under which a public company...more
12/20/2016
/ Disclosure Requirements ,
Financial Markets ,
Pharmaceutical Industry ,
Public Offerings ,
Publicly-Traded Companies ,
Rule 10(b) ,
Securities ,
Securities Exchange Act ,
Securities Fraud ,
Securities Litigation ,
Securities Violations ,
Stock Promoters ,
Stocks ,
Third-Party Agents